Better Growth Stock: AbbVie vs. Abbott Laboratories
Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue last year -- far more than Abbott's top line, which totaled just under $44 billion.
But today, AbbVie faces some challenges as its top-selling drug Humira is losing patent protection and its sales have been declining sharply. Abbott, meanwhile, isn't just some stale business. Its diabetes products have been generating impressive growth, and the company is also getting into consumer wearables.
Moving forward, which business is the better option for growth-oriented investors? Let's see.
Source Fool.com
Abbott Laboratories Stock
€96.31
-0.520%
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Abbott Laboratories.
As a result the target price of 116 € shows a positive potential of 20.44% compared to the current price of 96.31 € for Abbott Laboratories.
